DaVita's origin traces to 1999, when Total Renal Care, a California-based dialysis provider, merged with Renal Treatment Centers to form a new company that would be renamed DaVita—Italian for 'giving life.' The merger created a national dialysis provider with approximately 300 centers, but the company struggled operationally and financially in its early years. The turning point came in 1999 when Kent Thiry was recruited as CEO. Thiry, a former consultant and executive at Vivra Specialty Partners, implemented a transformative strategy that included cultural renewal, operational discipline, and aggressive expansion. He established DaVita's distinctive corporate culture, which emphasized teamwork, continuous improvement, and a 'village' concept that treated each dialysis center as a community. The defining transaction in DaVita's history occurred in 2005 when the company acquired Gambro Healthcare's US dialysis business for approximately $3.5 billion. Gambro was the third-largest dialysis provider in the United States, and the acquisition more than doubled DaVita's size, creating a national network of approximately 1,500 centers. The deal was financed with debt and equity, and it transformed DaVita into a true competitor to Fresenius Medical Care in the US dialysis duopoly. Following the Gambro acquisition, DaVita pursued diversification through the 2012 acquisition of HealthCare Partners, a large physician group management company, for approximately $4.42 billion. HealthCare Partners operated medical groups in California, Colorado, Florida, Nevada, New Mexico, and Washington, providing primary and specialty care to approximately 1.7 million patients. The acquisition was intended to create an integrated care platform that would position DaVita for value-based care and population health management. However, the HealthCare Partners acquisition proved challenging. The physician group management business had different economics, regulatory requirements, and competitive dynamics than dialysis. In 2017, DaVita announced the sale of DaVita Medical Group (the renamed HealthCare Partners) to Optum for approximately $4.9 billion. The sale, completed in 2019, returned DaVita to its core kidney care focus and generated significant cash for share repurchases and debt reduction. Under Javier Rodriguez, who became CEO in 2019 after serving as COO, DaVita has pursued a strategy of operational efficiency, integrated kidney care, and aggressive capital returns. The company has repurchased billions of dollars in stock, maintained its dialysis market position, and expanded internationally. In 2020, Berkshire Hathaway began accumulating DaVita shares, eventually reaching approximately 45% ownership by 2025. Warren Buffett's investment has provided both financial stability and strategic validation, though it also creates concentration risk in the shareholder base.